BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27863926)

  • 1. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
    Kang HG; Wang BZ; Zhang J; Liu MR; Li YX
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):197-203. PubMed ID: 27863926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-rapamycin combination was superior to mono-drug in treatment of hepatocellular carcinoma both in vitro and in vivo.
    Li XZ; Sun YL; Cao LQ; Li MJ
    Neoplasma; 2016; 63(6):880-887. PubMed ID: 27565326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
    Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
    Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
    Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
    Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sinomenine hydrochloride inhibits human hepatocellular carcinoma cell growth in vitro and in vivo: involvement of cell cycle arrest and apoptosis induction.
    Lu XL; Zeng J; Chen YL; He PM; Wen MX; Ren MD; Hu YN; Lu GF; He SΧ
    Int J Oncol; 2013 Jan; 42(1):229-38. PubMed ID: 23165705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noscapine inhibits human hepatocellular carcinoma growth through inducing apoptosis in vitro and in vivo.
    Xu G; Niu Z; Dong J; Zhao Y; Zhang Y; Li X
    Neoplasma; 2016; 63(5):726-33. PubMed ID: 27468876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
    Xiong YQ; Sun HC; Zhu XD; Zhang W; Zhuang PY; Zhang JB; Xu HX; Kong LQ; Wu WZ; Qin LX; Tang ZY
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):505-12. PubMed ID: 20490863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
    Zou X; Liang J; Sun J; Hu X; Lei L; Wu D; Liu L
    J Pharmacol Sci; 2016 Aug; 131(4):233-40. PubMed ID: 27177453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
    Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
    Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.